A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail - 11/09/11
From Dermatology Research, University of California, San Franciscoa; the Department of Dermatology, Columbia Presbyterian Medical Center, New Yorkb; the University of Mississippi Medical Center, Jacksonc; University Hospitals of Clevelandd; the Department of Dermatology, Mt. Sinai Medical Center, Miami Beache; the Division of Dermatology, University of Texas Health Science Center, San Antoniof; and the Janssen Research Foundation, Titusville.g
Abstract |
Background: Onychomycosis is the most frequent cause of nail disease and represents 30% of all mycotic infections of the skin.
Objective: Our purpose was to compare the effectiveness and tolerability of intermittent dosing of itraconazole ("pulse therapy") with placebo in fingernail onychomycosis.
Methods: Seventy-three patients with clinically and mycologically diagnosed fingernailonychomycosis were randomly selected to receive itraconazole, 200 mg twice daily, or placebo for the first week of each month for 2 consecutive months; patients were observed for 19 weeks. Seventy-one patients received the study medication and were included in the safety analysis. Efficacy of treatment was evaluated in 46 patients.
Results: A significantly greater proportion of itraconazole-treated patients than placebo-treated patients achieved clinical success (77% vs 0%), mycologic success (73% vs 13%), and overall success (68% vs 0%). No itraconazole-treated patient had a clinical or mycologic relapse during the follow-up period. Ten itraconazole-treated patients (28%) and nine placebo-treated patients (26%) had adverse events. Three patients discontinued treatment for safety reasons.
Conclusion: Pulse therapy with itraconazole for 2 consecutive months produces significantly greater clinical, mycologic, and overall success than placebo. Short-term itraconazole pulse therapy for fingernail onychomycosis is effective and well tolerated.
(J Am Acad Dermatol 1997;36:231-5.)
Le texte complet de cet article est disponible en PDF.Plan
 | Reprint requests: Mary Jacko, DPM, Janssen Research Foundation, 1125 Trenton-Harbourton Rd., Titusville, NJ 08560. |
| 0190-9622/97/$5.00 + 0 16/1/77206 |
Vol 36 - N° 2
P. 231-235 - février 1997 Retour au numéro
Article précédent
- Fluorescence photography in the evaluation of hyperpigmentation in photodamaged skin
- Nikiforos Kollias, Robert Gillies, Carlos Cohén-Goihman, Scott B. Phillips, Joseph A. Muccini, Matthew J. Stiller, Lynn A. Drake, From the Department of Dermatology, Dermatology Clinical Investigations Unit, Massachusetts General Hospital.
- Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin
- Christian A. Sander, Christiane Pfeiffer, Albert M. Kligman, Gerd Plewig, From the Department of Dermatology, Ludwig-Maximilians-Universitaet, Municha; and the Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia.b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?